Keen Vision Acquisition Corporation
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology 2024-10-31 20:00
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction 2024-10-24 20:00
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation 2024-09-05 20:00
Keen Vision Acquisition Corporation Announces Closing of $149,500,000 Initial Public Offering and Full Exercise of Over-Allotment Option 2023-07-28 04:00
Keen Vision Acquisition Corporation Announces Pricing of $130,000,000 Initial Public Offering 2023-07-25 05:30
1